Wearable Microneedle Patch Continuously Tracks Cardiac Troponin to Detect Silent Post-Surgical Heart Injury
Nine of every ten heart injuries after non-cardiac surgery go undetected, and researchers at McMaster University say a wearable microneedle patch published Thursday in Science Advances could catch them before patients leave the hospital.
- Key Clinical Takeaways:
- A wearable patch tracks cardiac troponin continuously for several days through painless microneedles that sample fluid beneath the skin.
- About 20% of higher-risk patients suffer myocardial injury after non-cardiac surgery (MINS), and roughly 90% of those cases produce no symptoms.
- The technology, funded by the Canadian Institutes of Health Research, is moving toward commercialization through a startup called Aptec Health.
The study, led by Hanjia Zheng with coauthors from the University of Waterloo and McMaster University, describes a platform the researchers call the Differential Aptalyzer. It pairs antibodies, which capture proteins, with aptamers — short engineered strands of DNA or RNA — that generate a reversible electrochemical signal.
According to the paper in Science Advances, the sensor detects cardiac troponin I across a range of 0.003 to 0.640 nanograms per milliliter and reliably tracked both rising and falling troponin levels in mouse models.
The clinical problem it targets is stark. Roughly 300 million people undergo non-cardiac surgery each year, and a growing share are sent home the same day. Yet the days after discharge carry elevated risk: about 20% of higher-risk patients experience MINS, and the injury is diagnosed mainly through blood tests that are hard to arrange once a patient is home.
Why 90% of injuries stay silent
Myocardial injury after non-cardiac surgery usually produces no obvious symptoms, which is why the field depends on troponin testing. Continuous monitors already exist for glucose, but proteins are far harder to track: cardiac troponin circulates at very low concentrations and is even more diluted in interstitial fluid, the liquid surrounding cells that the patch samples.
“That’s what makes this such an important advance. We’re monitoring a protein that’s present at very low levels and doing it continuously in living tissue,” said Leyla Soleymani, professor of engineering physics at McMaster and lead of engineering innovation at NexusHealth.
“About 90% of these cases are silent. The only way to diagnose many of them is through a blood test, which is difficult when patients are already home,” Soleymani said. “We wanted to develop a way to continuously monitor for heart injuries without requiring repeated blood draws.”
Two labs, one device
The patch rests on work split across two institutions. Engineers at the University of Waterloo built the hydrogel microneedles, which penetrate just beneath the skin without reaching nerves or blood vessels, and McMaster researchers handled the biosensing and aptamer engineering. Earlier versions of the platform tracked smaller molecules such as lactate; detecting proteins required the antibody-aptamer combination and a way to continuously refresh the sensor.
“Creating microneedles that can sample interstitial fluid comfortably and painlessly over extended periods and integrating them with sensing electrodes were key steps toward continuous wearable sensing,” said Mahla Poudineh, a study coauthor and associate professor at the NYU Tandon School of Engineering, whose group pioneered the polymeric microneedles.
Testing in living systems came from Bernardo Trigatti, professor of biochemistry and biomedical sciences at McMaster and a senior scientist at the Thrombosis and Atherosclerosis Research Institute of Hamilton Health Sciences. Trigatti’s team evaluated the device in mouse models of heart disease, including a double-knockout model of coronary artery disease with naturally elevated troponin — a step the paper describes as demonstrating the platform can identify coronary artery disease cohorts.
What the numbers say
| Measure | Figure | Source |
|---|---|---|
| Non-cardiac surgeries worldwide each year | About 300 million | McMaster University / Science Advances |
| Higher-risk patients who develop MINS | About 20% | McMaster University / Science Advances |
| MINS cases without symptoms | About 90% | McMaster University / Science Advances |
| Sensor detection range (troponin I) | 0.003–0.640 ng/mL | Science Advances |
The contrast between those first three numbers explains the urgency. A complication affecting one in five higher-risk patients is common by surgical standards; a complication that hides in nine of ten cases is hard to manage with anything but continuous data.
From lab bench to patients
The research team has received funding from the Canadian Institutes of Health Research to advance the technology through additional testing, and researchers are pursuing commercialization through Aptec Health, a startup founded for that purpose. The immediate focus is post-surgical monitoring, but Soleymani frames the ambition more broadly.
“The future of medicine is personalized, and personalized medicine needs data,” says Soleymani. Many of the most important health changes happen between clinic visits.
“I like working on hard problems, and I like working on meaningful problems. This one has both,” Soleymani said.
For now, the evidence base is preclinical. The Science Advances paper reports mouse data, not human trials, and no source in this reporting specifies when human testing or regulatory review would begin. Patients with questions about post-surgical cardiac risk or troponin monitoring can raise them with a cardiologist or perioperative physician familiar with current MINS screening practice, which still relies on blood-based troponin testing.
The open question is whether a patch that works in mice can hold its 0.003 to 0.640 nanogram-per-milliliter sensitivity on human skin, for days, outside a lab.
McMaster University, a public research university in Hamilton, Ontario, was incorporated in 1887 through the merger of Toronto Baptist College with Woodstock College’s faculty of theology, and named for William McMaster, a Canadian senator and banker whose bequest funded its founding.
It opened in Toronto in 1890 and relocated to Hamilton in 1930. Today it operates six academic faculties, including Engineering and Health Sciences, and is a member of the U15, a group of Canada’s research-intensive universities.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.